CHECKIT
23.11.2021 13:02:09 CET | Business Wire | Press release
Checkit’s intelligent operations platform will be rolled out to 441 bp forecourts in Australia and New Zealand following a new agreement with the multinational energy company.
Checkit has agreed a four-year partnership with bp Australia Pty Limited and bp Oil New Zealand Limited, following the successful completion of a pilot programme.
Checkit’s platform replaces paper-based processes with digital assistants in the form of a mobile app which prompts, guides and captures the activity of store assistants, and provides managers with real-time oversight. The platform also encompasses automated monitoring via fridge-mounted sensors and handheld temperature probes to enhance food safety, reduce waste and save time spent on manual checking routines.
The Checkit platform has already been effectively deployed at more than 320 bp-owned forecourts in the UK for more than 18 months. The rollout in Australia and New Zealand is the latest phase of Checkit’s expanding international partnership with bp.
Hannah Barnes, Vice President of Operational Excellence for Europe and Southern Africa at bp, said: “The Checkit platform has already delivered significant value across our UK retail operations by eradicating paperwork, saving staff time, reducing waste and providing data that enables us to optimise the availability of food at our Wild Bean Cafes. All of this contributes to better experiences for both our customers and our frontline teams. Checkit has been central to our intelligent store operations programme and its introduction to Australia and New Zealand is a natural evolution of that.”
Kit Kyte, CEO of Checkit, said: “The introduction of our platform into bp sites across Australia and New Zealand is a further affirmation of the importance of this technology in enabling intelligent operations across deskless workforces. The value can be seen in greater efficiency, improved staff engagement and retention, stock optimisation, production scheduling, waste reduction and many other measurable parameters. We have worked closely with bp to make this happen and look forward to continuing this valuable partnership.”
About Checkit
Checkit is the intelligent operations platform for deskless workforces, enabling operational agility and intelligent decision-making in large multinational and complex national organisations. The solution offers optional plugins for sensor networks and smart building management.
The Checkit Connect platform prompts, guides, captures and analyses frontline activities through digital workflows. Real-time data is captured from multiple workplaces. The platform empowers leaders to comprehend and continually improve processes, enhancing innovation, productivity, efficiency, energy usage, waste reduction, customer experience, safety and compliance.
Checkit provides intelligent operations tools to the retail, franchise, healthcare, life sciences, facilities management, catering, manufacturing, hospitality and commercial property sectors.
Checkit has customers including the NHS, bp, Waitrose, Sodexo and Center Parcs. The Checkit platform generates around 11bn data points per year from sensors and digital workflows.
Checkit is headquartered in Cambridge, UK, with its operations centre in Fleet, UK, and US office in Florida. The company has over 170 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
